A PHASE II STUDY OF THE FARNESYLTRANSFERASE INHIBITOR ZANESTRA (R115777, NSC #702818, IND #58,359) IN COMPLETE REMISSION FOLLOWING INDUCTION AND/OR CONSOLIDATION CHEMOTHERAPY IN ADULTS WITH POOR-RISK ACUTE MYELOGENOUS LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASIA (MDS):